JP2006514636A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514636A5
JP2006514636A5 JP2004557434A JP2004557434A JP2006514636A5 JP 2006514636 A5 JP2006514636 A5 JP 2006514636A5 JP 2004557434 A JP2004557434 A JP 2004557434A JP 2004557434 A JP2004557434 A JP 2004557434A JP 2006514636 A5 JP2006514636 A5 JP 2006514636A5
Authority
JP
Japan
Prior art keywords
composition
wta
infection
antibody
staphylococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004557434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038132 external-priority patent/WO2004050846A2/en
Publication of JP2006514636A publication Critical patent/JP2006514636A/ja
Publication of JP2006514636A5 publication Critical patent/JP2006514636A5/ja
Pending legal-status Critical Current

Links

JP2004557434A 2002-12-02 2003-12-01 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸 Pending JP2006514636A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43022502P 2002-12-02 2002-12-02
PCT/US2003/038132 WO2004050846A2 (en) 2002-12-02 2003-12-01 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines

Publications (2)

Publication Number Publication Date
JP2006514636A JP2006514636A (ja) 2006-05-11
JP2006514636A5 true JP2006514636A5 (enExample) 2007-06-07

Family

ID=32469426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004557434A Pending JP2006514636A (ja) 2002-12-02 2003-12-01 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸

Country Status (6)

Country Link
US (1) US20040247605A1 (enExample)
EP (1) EP1567868A4 (enExample)
JP (1) JP2006514636A (enExample)
AU (2) AU2003298770A1 (enExample)
CA (1) CA2507711A1 (enExample)
WO (1) WO2004050846A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US20070071682A1 (en) * 2005-08-22 2007-03-29 Kokai-Kun John F Methods for testing vaccine candidates against bacterial infection in rodents
EP1933874A4 (en) * 2005-10-11 2010-03-03 Iogenetics Llc TARGETED BIOZIDS
AU2008292897B2 (en) * 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
US8598342B2 (en) 2008-06-12 2013-12-03 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
KR20110124060A (ko) * 2010-05-10 2011-11-16 부산대학교 산학협력단 Ｗｔａ를 유효성분으로 함유하는 백신 조성물
WO2013071409A1 (en) 2011-11-18 2013-05-23 National Research Council Of Canada (Nrc) Clostridium difficile lipoteichoic acid and uses thereof
CN103383354B (zh) * 2012-05-03 2016-11-09 北京博迈世纪生物技术有限公司 一种检测肠毒素sea的磁微粒化学发光试剂盒的检测方法
KR20150024315A (ko) * 2012-05-07 2015-03-06 재단법인 목암생명공학연구소 포도상구균 감염 예방용 백신 조성물
CA2910029A1 (en) * 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
US20140356375A1 (en) * 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
JP6506262B2 (ja) * 2013-05-31 2019-04-24 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
EP3150217A1 (en) * 2014-05-29 2017-04-05 Green Cross Corporation Composition for preventing or treating staphylococcus aureus infection
MX2017007055A (es) * 2014-12-03 2017-11-08 Genentech Inc Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
WO2017010845A1 (ko) * 2015-07-15 2017-01-19 재단법인 목암생명과학연구소 포도상구균 감염 질환의 예방 또는 치료용 조성물
CA3024476A1 (en) * 2016-05-18 2017-11-23 Genmab B.V. Antibodies and methods of use thereof in treatment of infectious disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250262A (en) * 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
US5139933A (en) * 1989-09-26 1992-08-18 Vicam, L.P. Assay method for detecting listeria
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5290707A (en) * 1991-11-25 1994-03-01 The United States Of America As Represented By The Secretary Of The Army Method for detection of microorganisms
US5367058A (en) * 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
JP3814290B2 (ja) * 1993-12-09 2006-08-23 エスクナー，ハインリッヒ 抗原用のアジュバントおよびその製法ならびに用途
US6350597B1 (en) * 1994-01-13 2002-02-26 E. I. Du Pont De Nemours & Company Riboflavin synthase genes and enzymes and methods of use
US6203997B1 (en) * 1994-06-08 2001-03-20 Sepsis, Inc. Quantitation of analytes in whole blood
ATE219146T1 (de) * 1995-01-30 2002-06-15 Lunamed Ag Antitumorpräparate, die eine lipoteichonsäure aus streptococcus enthalten
JP4709333B2 (ja) * 1995-10-13 2011-06-22 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ホスホパンテテイニルトランスフェラーゼおよびその使用
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5889171A (en) * 1997-07-18 1999-03-30 Smithkline Beecham Corporation TarF
IL134056A0 (en) * 1997-07-23 2001-04-30 Ambi Inc Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6585973B1 (en) * 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
US6812021B1 (en) * 1998-12-22 2004-11-02 Microscience Limited Genes and proteins and their use
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
JP2002542182A (ja) * 1999-04-16 2002-12-10 オセル・インコーポレーテッド 粘膜上の可溶性ウイルス特異リガンドの半減期を増加させる方法
US6974700B2 (en) * 1999-06-14 2005-12-13 Martin Levine Kit for use in predicting refractory periodontal disease
AU2001288961A1 (en) * 2000-09-12 2002-06-18 U.S. Army Medical Research And Materiel Command Lipoteichoic acid immunogenic compositions and methods of making and using thereof
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
JP2005526497A (ja) * 2002-02-04 2005-09-08 ビオミラ，インコーポレーテッド 免疫刺激性、共有結合性脂質化オリゴヌクレオチド
FR2842210B1 (fr) * 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
US7348420B2 (en) * 2003-04-25 2008-03-25 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
US7422755B2 (en) * 2004-01-15 2008-09-09 The United States Of America As Represented By The Department Of Health And Human Services Antimultiorganism glycoconjugate vaccine
KR100596443B1 (ko) * 2004-04-27 2006-07-05 주식회사 하이닉스반도체 다수 뱅크 구조 디램을 위한 리프레시 제어회로 및 그 방법
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
BRPI0610609A2 (pt) * 2005-04-15 2010-07-06 Univ North Carolina State métodos e composições para modular a adesão e toleráncia ao estresse em bactérias
US7521535B2 (en) * 2006-09-20 2009-04-21 The Board Of Regents For Oklahoma State University Anti-microbial defensin-related peptides and methods of use

Similar Documents

Publication Publication Date Title
JP2006514636A5 (enExample)
JP2022031635A5 (enExample)
JP2021063090A5 (enExample)
JP2017512193A5 (enExample)
JP2019518742A5 (enExample)
JP2007511593A5 (enExample)
JP2016507470A5 (enExample)
JP2015534579A5 (enExample)
CA2544920A1 (en) Method for the treatment of multiple sclerosis by inhibiting il-17 activity
JP2019031565A5 (enExample)
JP2013515079A5 (enExample)
JP2017514461A5 (enExample)
JP2018535650A5 (enExample)
JP2012121878A5 (enExample)
JP2017507652A5 (enExample)
JP2007510639A5 (enExample)
JP2009511480A5 (enExample)
JP2015534578A5 (enExample)
JP2008538564A5 (enExample)
RU2016130056A (ru) Способы лечения кожной инфекции путем введения антагониста il-4r
JP2014525933A5 (enExample)
RU2016116949A (ru) Анти-лпс о11-антитело
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
JP2014524902A5 (enExample)
JP2014519334A5 (enExample)